Skip to main content
Sai Life Sciences Limited logo

Sai Life Sciences Limited — Investor Relations & Filings

Ticker · SAILIFE ISIN · INE570L01029 LEI · 335800JBS3NY25NIBC93 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 233 across all filing types
Latest filing 2025-08-28 Capital/Financing Update
Country IN India
Listing BSE.NS SAILIFE

About Sai Life Sciences Limited

https://www.sailife.com

Sai Life Sciences Limited is a full-service Contract Research, Development, and Manufacturing Organization (CRO-CDMO) that partners with global pharmaceutical and biotechnology innovators to accelerate the discovery, development, and commercialization of complex small molecules. The company provides an integrated platform of services spanning discovery chemistry and biology, DMPK, toxicology, process development, analytical R&D, and commercial-scale manufacturing. With a focus on operational excellence and regulatory compliance, it operates state-of-the-art R&D and manufacturing facilities. Its value proposition centers on the Sai Nxt initiative, which emphasizes investments in advanced technologies, expanded capacity, and a global delivery model designed to reduce time-to-market for novel therapeutics.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated 28 August 2025 from Sai Life Sciences Limited announcing the completion of Phase II of a production block at their manufacturing facility. It is addressed to stock exchanges and references a prior intimation. The content focuses on operational updates about production capacity expansion and includes quotes from the CEO. There are no financial statements, regulatory filings, voting results, or management discussions. The document is a corporate announcement about production capacity expansion, which fits best under Capital/Financing Update (CAP) as it relates to operational capacity expansion and investment in production facilities. The document length is about 4700 characters, which is consistent with a press release rather than a full report. Therefore, the classification is CAP with high confidence.
2025-08-28 English
ESOP/ESOS/ESPS
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the allotment of equity shares under Employees Stock Option Plans (ESOP 2008 and MESOP 2018). It includes detailed disclosures required under SEBI regulations about the share allotment, exercise prices, number of shares issued, and other compliance details. The document is an intimation or announcement of the allotment of shares pursuant to the exercise of stock options, not a financial report or earnings release. It is regulatory in nature, providing information about capital changes related to employee stock options. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share allotments under ESOPs.
2025-08-23 English
Copy of Newspaper Publication
Regulatory Filings
2025-08-19 English
Shareholders meeting
Annual Report Classification · 95% confidence The document is a Notice of the 26th Annual General Meeting (AGM) of Sai Life Sciences Limited, dated August 18, 2025, addressed to stock exchanges NSE and BSE. It references the Notice of the AGM as part of the Annual Report for the financial year 2024-25 and mentions that the Notice is being sent electronically to shareholders. The document also includes extensive content from the Annual Report 2024-25, including corporate overview, IPO listing details, company values, people and culture, and facilities. The length of the document (15,000 characters) and the inclusion of detailed company information and financial highlights indicate it is the full Annual Report rather than just an announcement or notice. Therefore, the document is best classified as an Annual Report (10-K).
2025-08-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the transcript of an earnings call for the unaudited financial results for the quarter ended June 30, 2025. It states that the transcript is attached and also uploaded on the company's website. The document itself does not contain the transcript text or financial data, but is an announcement of the transcript's availability. The document length is short (1555 characters), consistent with an announcement rather than the full transcript. According to the rules, announcements of transcripts or reports that are short and refer to the report being attached or available online should be classified as Regulatory Filings (RNS).
2025-08-18 English
Credit Rating- Revision
Capital/Financing Update Classification · 95% confidence The document is a detailed press release and rating upgrade report from India Ratings & Research Pvt. Ltd. regarding Sai Life Sciences Limited's bank loan ratings. It includes extensive financial performance data for FY25 and 1QFY26, detailed rationale for the rating upgrade, business profile, financial metrics, liquidity, and outlook. The document is not a full annual report but a credit rating update and analysis. It is not a simple announcement or certification but contains substantive financial data and analysis related to the company's credit rating. This fits best under the category of Capital/Financing Update (CAP), as it relates to the company's credit rating upgrade and financial health impacting its capital structure and financing costs.
2025-08-14 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.